Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile

被引：138

作者：

Schoch, C ^{[1
]}

Kern, W ^{[1
]}

Kohlmann, A ^{[1
]}

Hiddemann, W ^{[1
]}

Schnittger, S ^{[1
]}

Haferlach, T ^{[1
]}

机构：

[1] Univ Munich, Lab Leukemia Diagnost, Hosp Grosshadern, D-81377 Munich, Germany

来源：

GENES CHROMOSOMES & CANCER | 2005年 / 43卷 / 03期

关键词：

D O I：

10.1002/gcc.20193

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acute myeloid leukemia (AML) with a complex aberrant karyotype is a distinct biological entity. It is characterized by: (1) a sharp increase in incidence above age 50; (2) a characteristic pattern of chromosomal gain and, especially, loss, that is, of 5q14q33q35, and 17p13, translating into reduced expression of genes in these regions; (3) a unique gene expression pattern including up-regulation of genes involved in DNA repair; (4) a high incidence of TP53 deletions and/or mutations; and (5) an overall unfavorable prognosis. Further unraveling the biology of AML with a complex aberrant karyotype by gene expression profiling may provide deeper insights into the pathogenesis of as well as the reasons for chemoresistance in this AML subtype. These data may be the basis for developing targeted therapeutic strategies to increase the cure rate in patients with AML and a complex aberrant karyotype. (c) 2005 Wiley-Liss, Inc.

引用

页码：227 / 238

页数：12

共 59 条

[1] Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21:: Amplification discloses overexpression of APP, ETS2, and ERG genes [J].

Baldus, CD ;

Liyanarachchi, S ;

Mrózek, K ;

Auer, H ;

Tanner, SM ;

Guimond, M ;

Ruppert, AS ;

Mohamed, N ;

Davuluri, RV ;

Caligiuri, MA ;

Bloomfield, CD ;

de la Chapelle, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (11) :3915-3920

[2]

BenYehuda D, 1996, BLOOD, V88, P4296

[3]

BLOOMFIELD C D, 1984, Cancer Genetics and Cytogenetics, V11, P332

[4] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[5] Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis [J].

Christiansen, DH ;

Andersen, MK ;

Pedersen-Bjergaard, J .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1405-1413

[6] De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19 [J].

Cigudosa, JC ;

Odero, MD ;

Calasanz, MJ ;

Solé, F ;

Salido, M ;

Arranz, E ;

Martínez-Ramirez, A ;

Urioste, M ;

Alvarez, S ;

Cervera, JV ;

MacGrogan, D ;

Sanz, MA ;

Nimer, SD ;

Benitez, J .

GENES CHROMOSOMES & CANCER, 2003, 36 (04) :406-412

[7]

DASTUGUE N, 1995, LEUKEMIA, V9, P1491

[8] Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders [J].

Döhner, K ;

Brown, J ;

Hehmann, U ;

Hetzel, C ;

Stewart, J ;

Lowther, G ;

Scholl, C ;

Fröhling, S ;

Cuneo, A ;

Tsui, LC ;

Lichter, P ;

Scherer, SW ;

Döhner, H .

BLOOD, 1998, 92 (11) :4031-4035

[9] CYTOGENETICS AND THEIR PROGNOSTIC VALUE IN DENOVO ACUTE MYELOID-LEUKEMIA - A REPORT ON 283 CASES [J].

FENAUX, P ;

PREUDHOMME, C ;

LAI, JL ;

MOREL, P ;

BEUSCART, R ;

BAUTERS, F .

BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (01) :61-67

[10] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].

Grimwade, D ;

Walker, H ;

Oliver, F ;

Wheatley, K ;

Harrison, C ;

Harrison, G ;

Rees, J ;

Hann, I ;

Stevens, R ;

Burnett, A ;

Goldstone, A .

BLOOD, 1998, 92 (07) :2322-2333

← 1 2 3 4 5 6 →